- Home
- AEON vs ATNF Comparison
AEON vs ATNF Comparison
Compare AEON & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- ATNF
- Stock Information
- Founded
- AEON N/A
- ATNF 2016
- Country
- AEON United States
- ATNF United States
- Employees
- AEON N/A
- ATNF N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- ATNF Health Care
- Exchange
- AEON Nasdaq
- ATNF Nasdaq
- Market Cap
- AEON 4.2M
- ATNF 4.1M
- IPO Year
- AEON N/A
- ATNF N/A
- Fundamental
- Price
- AEON $0.46
- ATNF $0.86
- Analyst Decision
- AEON Strong Buy
- ATNF
- Analyst Count
- AEON 1
- ATNF 0
- Target Price
- AEON $360.00
- ATNF N/A
- AVG Volume (30 Days)
- AEON 465.0K
- ATNF 136.6K
- Earning Date
- AEON 05-13-2025
- ATNF 05-14-2025
- Dividend Yield
- AEON N/A
- ATNF N/A
- EPS Growth
- AEON N/A
- ATNF N/A
- EPS
- AEON 72.93
- ATNF N/A
- Revenue
- AEON N/A
- ATNF N/A
- Revenue This Year
- AEON N/A
- ATNF N/A
- Revenue Next Year
- AEON N/A
- ATNF N/A
- P/E Ratio
- AEON $0.01
- ATNF N/A
- Revenue Growth
- AEON N/A
- ATNF N/A
- 52 Week Low
- AEON $0.38
- ATNF $0.66
- 52 Week High
- AEON $402.48
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- AEON 26.87
- ATNF 41.22
- Support Level
- AEON $0.38
- ATNF $0.80
- Resistance Level
- AEON $0.43
- ATNF $0.94
- Average True Range (ATR)
- AEON 0.04
- ATNF 0.11
- MACD
- AEON 0.20
- ATNF 0.02
- Stochastic Oscillator
- AEON 56.29
- ATNF 42.78
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.